Mufg Securities Americas Inc. Buys 25,689 Shares of Pfizer Inc. $PFE

Mufg Securities Americas Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 25.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,004 shares of the biopharmaceutical company’s stock after buying an additional 25,689 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Pfizer were worth $3,054,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter worth approximately $27,000. Curio Wealth LLC lifted its holdings in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new position in shares of Pfizer in the first quarter worth approximately $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the second quarter worth $29,000. Finally, Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer during the 2nd quarter valued at $33,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PFE shares. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Scotiabank started coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Stock Up 2.5%

NYSE PFE opened at $25.02 on Friday. The stock has a 50 day moving average price of $24.84 and a 200-day moving average price of $24.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $142.26 billion, a P/E ratio of 13.31, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.